All News

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

My first oncologist was the nicest man. I only gave him up because we moved to a different state.

“I have found many survivors to be very strong women who seem like they have things under control but it’s always important for family and friends to check in,” television personality, author and breast cancer survivor Giuliana Rancic told CURE.

Now having conquered three cancers and am fighting metastatic pancreatic cancer, scars from all the surgeries within the last 26 years have shown victories and hope.

Patients with advanced-stage melanoma continue to experience reduced risk of recurrence or death following treatment with a combination of mRNA vaccine mRNA-4157 (V940) and Keytruda, an anti-PD-1 therapy, according to recent study findings.

Results from a study found that child-related factors and depression in mothers with breast cancer were not related to cancer.

The Food and Drug Administration has approved Padcev plus Keytruda to treat patients with locally advanced or metastatic bladder cancer.

My life in poems - check it out!

As Anna “Chickadee” Cardwell from “Here Comes Honey Boo Boo” dies from cancer and former tennis player Chris Evert announces cancer diagnosis, here is what’s happening in the oncology space this week.

Undergoing next-generation sequencing before receiving treatment can benefit patients with lung cancer and their doctors, as one expert told CURE®.

The Food and Drug Administration has approved Welireg for patients with advanced renal cell carcinoma, a type of kidney cancer, following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

An expert explained how ableism is present in cancer care, including chemotherapy eligibility, and how more awareness is needed in this space.

An expert explains the significance of the recent approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) by the Food and Drug Administration.

A great gift for a patient with cancer during the holidays is to create a positive memory.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Data showed that metabolic and genetic factors could contribute to aggressive tumors in Latin American and non-Hispanic White patients with breast cancer.

The Food and Drug Administration approved Iwilfin for high-risk neuroblastoma in adult and pediatric patients who previously had at least a partial response to a multiagent, modality therapy.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of Yescarta for patients with high-risk large B-cell lymphoma.

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

Growing up in a dysfunctional family left the holidays with little to be desired.

Dr. Lucia Masarova sat down with CURE® and discussed the advancements she hopes to see in 2024 for the treatment of patients with myeloproliferative neoplasms.

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A breast cancer survivor explains “one of the beautiful things” about antibody drug conjugates in the metastatic breast cancer space.

Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy.

Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.

Could killing cancer be as simple as changing your diet?

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

Results from an ongoing phase 2 study show the viability for the use of Brukinsa after patients with previously treated B-cell malignancies are deemed intolerant to the next-generation Bruton tyrosine kinase inhibitor Calquence.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.